PT  - JOURNAL ARTICLE
AU  - Mak, Jonathan K. L.
AU  - Eriksdotter, Maria
AU  - Annetorp, Martin
AU  - Kuja-Halkola, Ralf
AU  - Kananen, Laura
AU  - Boström, Anne-Marie
AU  - Kivipelto, Miia
AU  - Metzner, Carina
AU  - Jerlardtz, Viktoria Bäck
AU  - Engström, Malin
AU  - Johnson, Peter
AU  - Lundberg, Lars Göran
AU  - Åkesson, Elisabet
AU  - Öberg, Carina Sühl
AU  - Olsson, Maria
AU  - Cederholm, Tommy
AU  - Hägg, Sara
AU  - Religa, Dorota
AU  - Jylhävä, Juulia
TI  - Using an electronic frailty index to predict adverse outcomes in geriatric COVID-19 patients: data from the Stockholm GeroCovid study
AID  - 10.1101/2021.12.03.21267254
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.03.21267254
4099  - http://medrxiv.org/content/early/2021/12/05/2021.12.03.21267254.short
4100  - http://medrxiv.org/content/early/2021/12/05/2021.12.03.21267254.full
AB  - Background The Clinical Frailty Scale (CFS) is a strong predictor for worse outcomes in geriatric COVID-19 patients, but it is less clear whether an electronic frailty index (eFI) constructed from routinely collected electronic health records (EHRs) provides similar predictive value. This study aimed to investigate the predictive ability of an eFI in comparison to other frailty and comorbidity measures, using mortality, readmission, and the length of stay as outcomes in geriatric COVID-19 patients.Methods We conducted a retrospective cohort study using EHRs from nine geriatric clinics in Stockholm, Sweden, comprising 3,405 COVID-19 patients (mean age 81.9 years) between 1/3/2020 and 31/10/2021. Frailty was assessed using a 48-item eFI developed for Swedish geriatric patients, the CFS, and Hospital Frailty Risk Score (HFRS). Comorbidity was measured using the Charlson Comorbidity Index (CCI). We analyzed in-hospital mortality and 30-day readmission using logistic regression and area under receiver operating characteristic curve (AUC). 30-day and 6-month mortality were modelled by Cox regression, and the length of stay by linear regression.Results Controlling for age and sex, a 10% increase in the eFI was associated with higher risks of in-hospital mortality (odds ratio [OR]=2.84; 95% confidence interval=2.31-3.51), 30-day mortality (hazard ratio [HR]=2.30; 1.99-2.65), 6-month mortality (HR=2.33; 2.07-2.62), 30-day readmission (OR=1.34; 1.06-1.68), and longer length of stay (β=2.28; 1.90-2.66).The CFS, HFRS and CCI similarly predicted these outcomes, but the eFI had the best predictive accuracy for in-hospital mortality (AUC=0.775).Conclusions An eFI based on routinely collected EHRs can be applied in identifying high-risk geriatric COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported financially by the Swedish Research Council grants (2018-02077, 2020-02014, 2020-06101), the regional agreement on medical training and clinical research between the Stockholm County Council and the Karolinska Institutet (ALF), the Strategic Research Area in Epidemiology and Biostatistics grant, the Academy of Finland through its funding to the Centre of Excellence in Research of Ageing and Care (CoEAgeCare, grant numbers 335870, 326567 and 336670), Lakarsallskapet and Gosta Miltons Donationsfond grant, and the Stockholm University - Region Stockholm grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Swedish Ethical Review Authority (Dnr 2020-02146, 2020-03345, 2021-00595, 2021-02096).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.